These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18161933)

  • 41. Long-term outcome of transcatheter arterial chemoembolization after radiofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma.
    Xu RC; Liu HC; Li JL; Li K; Ou SY; Yu ZY; Kong Y; Ma GA; Shao WS
    Curr Med Res Opin; 2015 Aug; 31(8):1553-60. PubMed ID: 26067770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma.
    He Q; Lu WS; Liu Y; Guan YS; Kuang AR
    World J Gastroenterol; 2013 Dec; 19(47):9104-10. PubMed ID: 24379637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
    Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
    J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinico-roentogenologic findings in hepatocellular carcinoma fed by the right inferior phrenic artery at the initial chemoembolization.
    Kimura S; Okazaki M; Higashihara H; Haruno M; Nozaki Y; Urakawa H; Kora S; Shinagawa Y; Nonokuma M
    Hepatogastroenterology; 2009; 56(89):191-8. PubMed ID: 19453056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transcatheter arterial chemoembolization of hepatocellular carcinoma with hepatic arteriovenous shunt after temporary balloon occlusion of hepatic vein.
    Lee JH; Won JH; Park SI; Won JY; Lee DY; Kang BC
    J Vasc Interv Radiol; 2007 Mar; 18(3):377-82. PubMed ID: 17377183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.
    Tian G; Liu J; Zhou JS; Chen W
    Anticancer Drugs; 2009 Jun; 20(5):389-95. PubMed ID: 19287305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization.
    Miyayama S; Matsui O; Taki K; Minami T; Ryu Y; Ito C; Nakamura K; Inoue D; Notsumata K; Toya D; Tanaka N; Mitsui T
    Cardiovasc Intervent Radiol; 2006; 29(1):39-48. PubMed ID: 16328697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical effect of terminal branches portal vein embolization combined with transcatheter arterial chemoembolization on liver neoplasms].
    Peng SY; Huang CY; Wang XA; Wang YF; Zhang YY; Li JT; Xu B; Liang X; Wang JW; Hong DF; Cai XJ
    Zhonghua Wai Ke Za Zhi; 2017 Sep; 55(9):655-660. PubMed ID: 28870049
    [No Abstract]   [Full Text] [Related]  

  • 50. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up.
    Guan YS; Liu Y; He Q; Li X; Yang L; Hu Y; La Z
    World J Gastroenterol; 2011 Apr; 17(16):2143-9. PubMed ID: 21547136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma.
    Yang DJ; Luo KL; Liu H; Cai B; Tao GQ; Su XF; Hou XJ; Ye F; Li XY; Tian ZQ
    Oncotarget; 2017 Jan; 8(2):2960-2970. PubMed ID: 27936465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors.
    Lu W; Li Y; He X; Chen Y
    Hepatogastroenterology; 2003; 50(54):2079-83. PubMed ID: 14696468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Zhou B; Yan Z; Liu R; Shi P; Qian S; Qu X; Zhu L; Zhang W; Wang J
    Radiology; 2016 Aug; 280(2):630-9. PubMed ID: 26885681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization.
    Siramolpiwat S; Punjachaipornpon T; Pornthisarn B; Vilaichone RK; Chonprasertsuk S; Tangaroonsanti A; Bhanthumkomol P; Phumyen A; Yasiri A; Kaewmanee M
    Dig Dis Sci; 2019 Nov; 64(11):3337-3345. PubMed ID: 31073737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of Embolization Area after Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using SYNAPSE VINCENT.
    Ogawa C; Minami Y; Morita M; Noda T; Arasawa S; Izuta M; Kubo A; Matsunaka T; Tamaki H; Shibatoge M; Kudo M
    Dig Dis; 2016; 34(6):696-701. PubMed ID: 27750240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oily chemoembolization combined with degradable starch microspheres for HCC with cirrhosis.
    Murata S; Tajima H; Ichikawa K; Onozawa S; Wang J; Kumita S; Nomura K
    Hepatogastroenterology; 2008; 55(84):1041-6. PubMed ID: 18705325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Transarterial Chemoembolization and Repeated Partial Splenic Embolization for Hepatocellular Carcinoma with Hypersplenism and Thrombocytopenia.
    Hong W; Wang Z; Yao W; Zhang X; Zhang L; Liang B
    J Hepatocell Carcinoma; 2024; 11():1065-1078. PubMed ID: 38882439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical effect of ultraselective transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma originating from the caudate lobe: an analysis of 13 cases].
    Yuan HJ; Liu FY; Li X; Guan Y; Zuo TY; Wang MQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):744-748. PubMed ID: 29108202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.